|8.77||-0.0600||-0.68%||Vol 964.42K||1Y Perf -42.21%|
|Jul 27th, 2021 14:08 DELAYED|
|-0.01 -0.11%||- -|
|Target Price||18.05||Analyst Rating||Strong Buy 1.22|
|Potential %||105.11||Finscreener Ranking||★★+ 47.97|
|Insiders Trans % 3/6/12 mo.||-56/-58/-56||Value Ranking||★ 40.22|
|Insiders Value % 3/6/12 mo.||-95/-94/-94||Growth Ranking||★★ 44.43|
|Insiders Shares Cnt. % 3/6/12 mo.||-94/-94/-95||Income Ranking||— -|
|Market Cap||2.33B||Earnings Rating||Sell|
|Price Range Ratio 52W %||1.01||Earnings Date||9th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Aug 2021|
|Estimated EPS Next Report||-0.21|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.75M|
|Avg. Monthly Volume||2.15M|
|Avg. Quarterly Volume||2.42M|
Amicus Therapeutics Inc. (NASDAQ: FOLD) stock closed at 8.83 per share at the end of the most recent trading day (a 0.11% change compared to the prior day closing price) with a volume of 1.71M shares and market capitalization of 2.33B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 584 people. Amicus Therapeutics Inc. CEO is John F. Crowley.
The one-year performance of Amicus Therapeutics Inc. stock is -42.21%, while year-to-date (YTD) performance is -61.76%. FOLD stock has a five-year performance of 23.84%. Its 52-week range is between 8.6 and 25.39, which gives FOLD stock a 52-week price range ratio of 1.01%
Amicus Therapeutics Inc. currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 9.35, a price-to-sale (PS) ratio of 11.48, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.75%, a ROC of -36.60% and a ROE of -77.60%. The company’s profit margin is -98.37%, its EBITDA margin is -80.40%, and its revenue ttm is $204.41 Million , which makes it $0.77 revenue per share.
Of the last four earnings reports from Amicus Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Amicus Therapeutics Inc.’s next earnings report date is 09th Aug 2021.
The consensus rating of Wall Street analysts for Amicus Therapeutics Inc. is Strong Buy (1.22), with a target price of $18.05, which is +105.11% compared to the current price. The earnings rating for Amicus Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amicus Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amicus Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.13, ATR14 : 0.39, CCI20 : -111.63, Chaikin Money Flow : -0.09, MACD : -0.26, Money Flow Index : 62.32, ROC : -5.96, RSI : 39.37, STOCH (14,3) : 20.91, STOCH RSI : 0.16, UO : 41.21, Williams %R : -79.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amicus Therapeutics Inc. in the last 12-months were: Bradley L. Campbell (Option Excercise at a value of $505 920), Bradley L. Campbell (Sold 52 570 shares of value $643 770 ), Burke W. Whitman (Buy at a value of $126 707), Daphne Quimi (Option Excercise at a value of $48 886), John F. Crowley (Option Excercise at a value of $802 873), John F. Crowley (Sold 257 432 shares of value $3 584 975 ), Margaret G. McGlynn (Option Excercise at a value of $75 100), Margaret G. McGlynn (Sold 10 000 shares of value $102 704 ), Michael G. Raab (Option Excercise at a value of $42 593)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.